Immunotherapy Programs

Dec 22, 2023 | cell.com | Saravanan Raju |Lucas Adams |Michael Diamond |Immunotherapy Programs

Highlights Proteinaceous receptors bind distinct sites of the alphavirus glycoprotein to mediate efficient cellular entry. The cleft formed by E1–E2 heterodimers is utilized by the mammalian MXRA8 to bind Chikungunya virus (CHIKV) and LDLRAD3 to bind Venezuelan equine encephalitis virus (VEEV).

Aug 10, 2023 | academic.oup.com | Immunotherapy Programs

Ebola virus (EBOV) is a highly pathogenic virus that encodes seven multifunctional structural proteins. Multiple host factors have been reported to interact with the EBOV proteins. Here, we found that Tripartite motif-containing 14 (TRIM14), an interferon-stimulated gene that mediates cellular signaling pathways associated with type I interferon and inflammatory cytokine production, interacts with EBOV nucleoprotein (NP) to enhance IFN-β and NF-κB promotor activation.

Feb 13, 2023 | journals.aai.org | Immunotherapy Programs

6 Geretti, A. M. , A. J. Stockdale, S. H. Kelly, M. Cevik, S. Collins, L. Waters, G. Villa, A. Docherty, E. M. Harrison, L. Turtle, et al. 2021. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin. Infect. Dis. 73: e2095–e2106.